The North America Carrier Screening Market is expected to witness market growth of 11.04% CAGR during the forecast period (2021-2027).
Carrier screening is the diagnosis of atypical chromosomal or genetic disorders from a carrier individual who inherits one abnormal gene from one of their parents. Carrier frequently displays zero symptoms of the genetic diseases that they forward an abnormal gene. Factors such as increasing cases of genetic diseases, growing availability & affordability of tests, and increasing launches of innovative products are likely to boost the growth and demand for the carrier screening market during the forecast period.
North America is the leading region of the carrier screening market and is expected to display the same trend even during the forecasting years. This is because Genetic disease is the major cause of infant deaths in the United States, responsible for around one-fifth of the total yearly infant mortality, according to the data published by the World Health Organization. The constant technological developments in genomic medicine and technological platforms have made feasible cost-effective, and pan-ethnic, expanded carrier screening that allows obstetric care vendors to provide screening for above 100 recessive genetic diseases.
The technology segment is expected to emerge as the leading segment during the forecasting period. This is credited to the constant developments in genetic analysis tools, like assays built on next-generation sequencing and microarray technologies, molecular diagnostics, and advancing the kind for heritable disorders.
The USA market dominated the North America Carrier Screening Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $737.7 million by 2027. The Canada market is experiencing a CAGR of 11.2% during (2021 - 2027). Additionally, The Mexico market is estimated to witness a CAGR of 13.3% during (2021 - 2027).
Based on Technology, the market is segmented into DNA Sequencing, Microarrays, Polymerase Chain Reaction and Other technology. Based on End user, the market is segmented into Hospital and Clinics, Physician Offices, Reference Laboratories and Other End Users. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics, Incorporated, Thermo Fisher Scientific, Illumina, Inc., Eurofins Scientific Group, Invitae Corporation, OPKO Health, Inc., Fulgent Genetics, Sema4 OpCo, Inc., Myriad Genetics, Inc., and Natera, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Expanded Carrier Screening and
- Targeted Disease Carrier Screening
By Technology
- DNA Sequencing
- Microarrays
- Polymerase Chain Reaction and
- Other technology
By End User
- Hospital and Clinics
- Physician Offices
- Reference Laboratories and
- Other End Users
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Quest Diagnostics, Incorporated
- Thermo Fisher Scientific
- Illumina, Inc.
- Eurofins Scientific Group
- Invitae Corporation
- OPKO Health, Inc.
- Fulgent Genetics
- Sema4 OpCo, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Quest Diagnostics, Incorporated
- Thermo Fisher Scientific
- Illumina, Inc.
- Eurofins Scientific Group
- Invitae Corporation
- OPKO Health, Inc.
- Fulgent Genetics
- Sema4 OpCo, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
Methodology
LOADING...
